United StatesNew guidelines for migraine prevention, developed by the American Headache Society and the American Academy of Neurology, emphasize the growing number of treatment options now available for patients. The guidelines update recommendations first issued in 2012 and highlight at least six FDA-approved medications introduced since then, many targeting the calcitonin gene-related peptide (CGRP) pathway linked to migraines. Doctors are advised to consider preventive treatment for individuals experiencing at least four migraine or severe headache days per month, or whose condition interferes with daily activities. Approximately 15% of Americans suffer from migraines, with women being disproportionately affected. Preventive treatments can significantly reduce headache frequency, though many patients are unaware they qualify. The guidelines cover both episodic and chronic migraines, noting newer therapies like CGRP inhibitors and older treatments like Botox and propranolol. Clinicians are encouraged to assess treatment effectiveness after eight to 12 weeks.
Bias read (Center): The article discusses medical guidelines related to migraine treatment, focusing on clinical recommendations and pharmaceutical advancements. There is no explicit political framing, ideological emphasis, or partisan language. The content remains focused on healthcare developments without leaning on,
